Status:
TERMINATED
CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
Lead Sponsor:
Sanofi
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary rationale for this study is to develop an optimized schedule of administration of FOLFOX + bevacizumab that maximizes the efficacy and safety of this regimen when administered to patients ...
Eligibility Criteria
Inclusion
- The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
- Histologically or cytologically documented metastatic, measurable adenocarcinoma of the colon, rectum, or appendix with no prior therapies for metastatic disease
- ECOG performance status (PS) of 0 or 1
- Adequate hematologic, renal, and hepatic function as defined by required baseline laboratory parameters
- No other serious concomitant disease.
Exclusion
- Peripheral neuropathy \> Grade 1 at baseline
- History of significant cerebrovascular, cardiovascular, or peripheral vascular disease
- Uncontrolled hypertension (defined as blood pressure \> 150/100 mmHg)
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, within 6 months prior to start of study drug
- Minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to start of study drug
- Serious, non-healing wound, ulcer, or bone fracture
- Active gastroduodenal ulcer
- Evidence of bleeding diathesis or coagulopathy
- Significant history of bleeding within 6 months prior to registration
- Prior history of hypertensive crisis or hypertensive encephalopathy
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00129870
Start Date
February 1 2005
End Date
December 1 2007
Last Update
February 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Bridgewater, New Jersey, United States, 08807